GENE ONLINE|News &
Opinion
Blog

2022-04-29| FundingTechnology

Boston’s Kelonia Therapeutics Bags $50M to Accelerate Genetic Medicines

by Fujie Tham
Share To

Kelonia Therapeutics, a biotech revolutionizing in-vivo gene delivery, launched with a $50 million Series A financing with backing of Alta Partners, Horizons Ventures, and Venrock to initiate a new era of targeted genetic therapies. 

Based on discoveries made in Michael Birnbaum’s lab at the Massachusetts Institute of Technology, and leveraging pioneering research from the French National Centre for Scientific Research (CNRS), Kelonia’s in-vivo gene delivery platform allows potent lentiviral vector particles armed with a flexible targeting system to deliver payloads exactly where they are needed to treat diseases. Combining CAR-T cells with in-vivo targeting, the result is off-shelf genetic therapeutics that can be administered directly.

The support from strong investors also pushed Kelonia into strategic collaborations with players like ElevateBio, which is also developing robust and integrated manufacturing pipelines.

Related Article: UK’s Autolus Receives RMAT Designation by FDA for CAR T Cell Therapy

 

Rapidly Growing Global Cell Therapy Market

 

As one of the most innovative therapies available in the market which uses the patients’ immune cells to fight cancer, the CAR-T market was projected to reach $20,566 million by 2029, rising at 31.6% CAGR.

Increase in cooperation and trials by drug makers to develop CAR-T cell therapies worldwide coupled with the rise in global public health push for cancer awareness is driving CAR-T cell therapy and is expected to further boost market growth.

“Kelonia is combining the two crucial elements required to develop truly novel medicines: breakthrough biology and an exceptional team,” said Bryan Roberts, Partner at Venrock. “Michael Birnbaum’s industrially robust platform affords a targeting specificity log orders better than anything else out there and the team has a stellar track record for translating groundbreaking scientific gene therapy discoveries into viable products that are transformative for patients.”

As the company begins accessing its core technology and expanding its portfolio, patients can anticipate more market-disturbing therapeutic innovations to be made available soon.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
Roche Dives Deeper into Off-The-Shelf Cell Therapies in Poseida Partnership
2022-08-04
BIO 2022: Addressing Bottlenecks in Gene Therapy
2022-08-03
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!